Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction

Completed · Phase 3 · Has a placebo group

Conditions studied: Chronic Heart Failure (CHF)

In brief

This study was a multi-center, randomized, double-blind, parallel group, active comparator trial designed to evaluate the overall effect of LCZ696 compared to valsartan on cognitive function as assessed by the CogState comprehensive cognitive battery in patients with Heart failure and preserved ejection fraction (HFpEF).

Key facts

Study ID
NCT02884206
Run by
Novartis Pharmaceuticals
People needed
592
Starts
2016-11-23
Expected to finish
2022-05-16
Last updated by the study team
2024-08-06

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.